Table 4.

Summary of reported 1-year efficacy and renal safety in past studies.

	Viral suppression (%, log IU/mL)		ALT normalization, %	HBsAg, log IU/mL	Cr, mg/dL	eGFR	Reference
Clinical trial, HBeAg (+), n = 581	64	6.06	72	NA	↑0.01	0.6∗	[4]
Clinical trial, HBeAg (−), n = 285	94	NA	83	0.09	↑0.01	1.8∗	[3]
Japan, n = 144 HBeAg (+)10 HBeAg (−)	NA	5.0	100	0.15	NA	2.3∗	[17]
Canada, n = 33	75	NA	NA	NA	NA	NA	[18]
Present study
n = 148	83.1	5.18	75.7	0.27	↑0.03	2.6†
42 HBeAg (+)	67.5	6.53	61.9	0.65	↑0.03	2.7†
106 HBeAg (−)	89.2	4.69	81.1	0.19	↑0.03	2.5†

ALT = alanine aminotransferase, eGFR = estimated glomerular filtration rate, NA = not available.

^∗mL/min.

^†mL/min/1.73 m².